Welcome guest, Login | Register


Susan L. Uprichard


Ph.D. in Virology, Department of Microbiology and Molecular Genetics, Harvard University, 1996

Current position

Associate Professor of Medicine and Microbiology/Immunology
Director of Hepatology Research
Basic Science Director, Clinical Research Office
Co-Director, Program of Experimental and Theoretical Modeling, Loyola University Medical Center
Maywood, IL, USA

Publications (since 2009)

  1. Uprichard, S. L. and Sainz, B. (2014). Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment. Gut. (Epub ahead of print)
  2. Sabahi, A., Uprichard, S. L., Wimley, W. C., Dash, S. and Garry, R. F. (2014). Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol 88(18): 10280-10288.
  3. Barretto, N., Sainz, B., Jr., Hussain, S. and Uprichard, S. L. (2014). Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread. J Virol 88(9): 5050-5061.
  4. Uprichard, S. L. (2014). Establishment of mice with inheritable susceptibility to productive hepatitis C virus infection. Hepatology 59(5): 2043-2046.
  5. Lee, H., Zhu, T., Patel, K., Zhang, Y. Y., Truong, L., Hevener, K. E., Gatuz, J. L., Subramanya, G., Jeong, H. Y., Uprichard, S. L. and Johnson, M. E. (2013). High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes. PLoS One 8(10): e75144.
  6. Guedj, J., Dahari, H., Uprichard, S. L. and Perelson, A. S. (2013). The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate. Expert Rev Gastroenterol Hepatol 7(5): 397-399.
  7. Martin, D. N. and Uprichard, S. L. (2013). Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A 110(26): 10777-10782.
  8. Guedj, J., Dahari, H., Rong, L., Sansone, N. D., Nettles, R. E., Cotler, S. J., Layden, T. J., Uprichard, S. L. and Perelson, A. S. (2013). Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 110(10): 3991-3996.
  9. Yu, X., Sainz, B., Jr., Petukhov, P. A. and Uprichard, S. L. (2012). Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob Agents Chemother 56(12): 6109-6120.
  10. Hussain, S., Barretto, N. and Uprichard, S. L. (2012). New hepatitis C virus drug discovery strategies and model systems. Expert Opin Drug Discov 7(9): 849-859.
  11. Sainz, B., Jr., Barretto, N., Yu, X., Corcoran, P. and Uprichard, S. L. (2012). Permissiveness of human hepatoma cell lines for HCV infection. Virol J 9: 30.
  12. Sainz, B., Jr., Barretto, N., Martin, D. N., Hiraga, N., Imamura, M., Hussain, S., Marsh, K. A., Yu, X., Chayama, K., Alrefai, W. A. and Uprichard, S. L. (2012). Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18(2): 281-285.
  13. Tencate, V., Sainz, B., Jr., Cotler, S. J. and Uprichard, S. L. (2010). Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat Med 2010(2): 125-145.
  14. Uprichard, S. L. (2010). Hepatitis C virus experimental model systems and antiviral drug research. Virol Sin 25(4): 227-245.
  15. Yu, X. and Uprichard, S. L. (2010). Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening. Curr Protoc Microbiol Chapter 17: Unit 17 15.
  16. Sabahi, A., Marsh, K. A., Dahari, H., Corcoran, P., Lamora, J. M., Yu, X., Garry, R. F. and Uprichard, S. L. (2010). The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology 407(1): 110-119.
  17. Cobleigh, M. A., Buonocore, L., Uprichard, S. L., Rose, J. K. and Robek, M. D. (2010). A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol 84(15): 7513-7522.
  18. Sainz, B., Jr., Barretto, N. and Uprichard, S. L. (2009). Hepatitis C virus infection in phenotypically distinct Huh7 cell lines. PLoS One 4(8): e6561.
  19. Yu, X., Sainz, B., Jr. and Uprichard, S. L. (2009). Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening. Antimicrob Agents Chemother 53(10): 4311-4319.
  20. Sainz, B., Jr., TenCate, V. and Uprichard, S. L. (2009). Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection. Virol J 6: 103.
  21. Li, L., Oropeza, C. E., Sainz, B., Jr., Uprichard, S. L., Gonzalez, F. J. and McLachlan, A. (2009). Developmental regulation of hepatitis B virus biosynthesis by hepatocyte nuclear factor 4alpha. PLoS One 4(5): e5489.
  22. Dahari, H., Sainz, B., Jr., Perelson, A. S. and Uprichard, S. L. (2009). Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J Virol 83(13): 6383-6390.
  23. Choi, S., Sainz, B., Jr., Corcoran, P., Uprichard, S. and Jeong, H. (2009). Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells. Xenobiotica 39(3): 205-217.
Protocols by Susan L. Uprichard
  1. Hepatitis C virus Cell-to-cell Spread Assay